Arch Biopartners Inc. (ARCH.V)
CAD 1.7
(-2.86%)
CAD 1.7
(-2.86%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 6.68 Million CAD | 31.2% |
| 2022 | 5.09 Million CAD | -22.26% |
| 2021 | 6.55 Million CAD | 42.12% |
| 2020 | 4.6 Million CAD | 32.85% |
| 2019 | 3.46 Million CAD | 101.91% |
| 2018 | 1.71 Million CAD | 172.19% |
| 2017 | 631.34 Thousand CAD | 30.46% |
| 2016 | 483.94 Thousand CAD | -4.74% |
| 2015 | 508.02 Thousand CAD | 23.19% |
| 2014 | 412.37 Thousand CAD | -10.78% |
| 2013 | 462.19 Thousand CAD | 2.89% |
| 2012 | 449.23 Thousand CAD | 13.15% |
| 2011 | 397.02 Thousand CAD | 7.18% |
| 2010 | 370.41 Thousand CAD | 6.58% |
| 2009 | 347.55 Thousand CAD | -86.49% |
| 2008 | 2.57 Million CAD | 30.33% |
| 2007 | 1.97 Million CAD | 23.52% |
| 2006 | 1.59 Million CAD | -21.86% |
| 2005 | 2.04 Million CAD | 1.47% |
| 2004 | 2.01 Million CAD | 28.74% |
| 2003 | 1.56 Million CAD | 3619.39% |
| 2002 | 42.08 Thousand CAD | -81.7% |
| 2001 | 229.98 Thousand CAD | -28.18% |
| 2000 | 320.2 Thousand CAD | 56.02% |
| 1999 | 205.23 Thousand CAD | -35.03% |
| 1998 | 315.9 Thousand CAD | -16.91% |
| 1997 | 380.17 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 8.09 Million CAD | -1.56% |
| 2024 Q2 | 8.22 Million CAD | 29.53% |
| 2024 Q1 | 6.34 Million CAD | -4.96% |
| 2023 Q4 | 6.68 Million CAD | -6.83% |
| 2023 FY | 6.68 Million CAD | 31.2% |
| 2023 Q2 | 9.12 Million CAD | 75.91% |
| 2023 Q1 | 5.18 Million CAD | 1.86% |
| 2023 Q3 | 7.17 Million CAD | -21.41% |
| 2022 Q1 | 5.55 Million CAD | -15.13% |
| 2022 Q4 | 5.09 Million CAD | -12.51% |
| 2022 FY | 5.09 Million CAD | -22.26% |
| 2022 Q2 | 5.91 Million CAD | 6.35% |
| 2022 Q3 | 5.82 Million CAD | -1.55% |
| 2021 Q1 | 5.53 Million CAD | 20.04% |
| 2021 Q2 | 6.07 Million CAD | 9.84% |
| 2021 Q3 | 7.52 Million CAD | 23.77% |
| 2021 Q4 | 6.55 Million CAD | -12.91% |
| 2021 FY | 6.55 Million CAD | 42.12% |
| 2020 Q3 | 4.41 Million CAD | 9.17% |
| 2020 FY | 4.6 Million CAD | 32.85% |
| 2020 Q1 | 3.6 Million CAD | 3.95% |
| 2020 Q2 | 4.04 Million CAD | 12.13% |
| 2020 Q4 | 4.6 Million CAD | 4.39% |
| 2019 Q2 | 2.42 Million CAD | 10.22% |
| 2019 Q4 | 3.46 Million CAD | 7.25% |
| 2019 Q3 | 3.23 Million CAD | 33.31% |
| 2019 Q1 | 2.2 Million CAD | 28.13% |
| 2019 FY | 3.46 Million CAD | 101.91% |
| 2018 Q1 | 1.12 Million CAD | 78.29% |
| 2018 FY | 1.71 Million CAD | 172.19% |
| 2018 Q3 | 1.66 Million CAD | 1.43% |
| 2018 Q2 | 1.63 Million CAD | 45.51% |
| 2018 Q4 | 1.71 Million CAD | 3.44% |
| 2017 Q3 | 562.03 Thousand CAD | 2.77% |
| 2017 Q1 | 577.61 Thousand CAD | 19.36% |
| 2017 Q2 | 546.88 Thousand CAD | -5.32% |
| 2017 Q4 | 631.34 Thousand CAD | 12.33% |
| 2017 FY | 631.34 Thousand CAD | 30.46% |
| 2016 Q4 | 483.94 Thousand CAD | -2.09% |
| 2016 Q3 | 494.25 Thousand CAD | 0.65% |
| 2016 Q2 | 491.06 Thousand CAD | 4.53% |
| 2016 Q1 | 469.79 Thousand CAD | -7.53% |
| 2016 FY | 483.94 Thousand CAD | -4.74% |
| 2015 Q3 | 411.57 Thousand CAD | -1.05% |
| 2015 Q4 | 508.02 Thousand CAD | 23.43% |
| 2015 Q1 | 458.64 Thousand CAD | 11.22% |
| 2015 Q2 | 415.96 Thousand CAD | -9.31% |
| 2015 FY | 508.02 Thousand CAD | 23.19% |
| 2014 Q1 | 517.07 Thousand CAD | 11.87% |
| 2014 Q4 | 412.37 Thousand CAD | -14.82% |
| 2014 Q3 | 484.11 Thousand CAD | 8.38% |
| 2014 Q2 | 446.66 Thousand CAD | -13.62% |
| 2014 FY | 412.37 Thousand CAD | -10.78% |
| 2013 Q4 | 462.19 Thousand CAD | -3.36% |
| 2013 FY | 462.19 Thousand CAD | 2.89% |
| 2013 Q3 | 478.26 Thousand CAD | 3.06% |
| 2013 Q2 | 464.06 Thousand CAD | 9.25% |
| 2013 Q1 | 424.75 Thousand CAD | -5.45% |
| 2012 Q3 | 417.57 Thousand CAD | -2.04% |
| 2012 FY | 449.23 Thousand CAD | 13.15% |
| 2012 Q1 | 411.43 Thousand CAD | 3.63% |
| 2012 Q2 | 426.28 Thousand CAD | 3.61% |
| 2012 Q4 | 449.23 Thousand CAD | 7.58% |
| 2011 Q2 | 396.77 Thousand CAD | -8.38% |
| 2011 FY | 397.02 Thousand CAD | 7.18% |
| 2011 Q3 | 396.56 Thousand CAD | -0.05% |
| 2011 Q1 | 433.03 Thousand CAD | 16.91% |
| 2011 Q4 | 397.02 Thousand CAD | 0.12% |
| 2010 FY | 370.41 Thousand CAD | 6.58% |
| 2010 Q4 | 370.41 Thousand CAD | -13.08% |
| 2010 Q2 | 370.09 Thousand CAD | 6.48% |
| 2010 Q1 | 347.55 Thousand CAD | 34.25% |
| 2010 Q3 | 426.17 Thousand CAD | 15.15% |
| 2009 FY | 347.55 Thousand CAD | -86.49% |
| 2009 Q1 | 2.57 Million CAD | -38.04% |
| 2009 Q2 | 2.06 Million CAD | -19.55% |
| 2009 Q4 | 258.89 Thousand CAD | 11.77% |
| 2009 Q3 | 231.62 Thousand CAD | -88.81% |
| 2008 FY | 2.57 Million CAD | 30.33% |
| 2008 Q1 | 1.97 Million CAD | -4.03% |
| 2008 Q2 | 2.67 Million CAD | 35.56% |
| 2008 Q3 | 2.96 Million CAD | 10.81% |
| 2008 Q4 | 4.15 Million CAD | 40.04% |
| 2007 Q3 | 1.51 Million CAD | -2.43% |
| 2007 Q1 | 1.59 Million CAD | -2.06% |
| 2007 Q2 | 1.55 Million CAD | -2.65% |
| 2007 FY | 1.97 Million CAD | 23.52% |
| 2007 Q4 | 2.05 Million CAD | 35.51% |
| 2006 FY | 1.59 Million CAD | -21.86% |
| 2006 Q4 | 1.63 Million CAD | 1.94% |
| 2006 Q3 | 1.6 Million CAD | -0.17% |
| 2006 Q2 | 1.6 Million CAD | -21.59% |
| 2006 Q1 | 2.04 Million CAD | 9.49% |
| 2005 Q4 | 1.86 Million CAD | 4.65% |
| 2005 Q3 | 1.78 Million CAD | -3.33% |
| 2005 Q2 | 1.84 Million CAD | -8.39% |
| 2005 Q1 | 2.01 Million CAD | -11.02% |
| 2005 FY | 2.04 Million CAD | 1.47% |
| 2004 Q3 | 1.87 Million CAD | 30.57% |
| 2004 Q1 | 1.56 Million CAD | 933.26% |
| 2004 Q2 | 1.43 Million CAD | -8.48% |
| 2004 FY | 2.01 Million CAD | 28.74% |
| 2004 Q4 | 2.26 Million CAD | 21.08% |
| 2003 Q4 | 151.48 Thousand CAD | 94.57% |
| 2003 Q3 | 77.85 Thousand CAD | -36.73% |
| 2003 Q2 | 123.06 Thousand CAD | 192.42% |
| 2003 Q1 | 42.08 Thousand CAD | -75.12% |
| 2003 FY | 1.56 Million CAD | 3619.39% |
| 2002 FY | 42.08 Thousand CAD | -81.7% |
| 2002 Q4 | 169.15 Thousand CAD | 7.74% |
| 2002 Q2 | 96.23 Thousand CAD | -58.16% |
| 2002 Q3 | 157 Thousand CAD | 63.16% |
| 2002 Q1 | 229.98 Thousand CAD | 0.0% |
| 2001 Q1 | 320.2 Thousand CAD | 0.0% |
| 2001 Q2 | 303.57 Thousand CAD | -5.19% |
| 2001 Q3 | 301.06 Thousand CAD | -0.83% |
| 2001 FY | 229.98 Thousand CAD | -28.18% |
| 2000 FY | 320.2 Thousand CAD | 56.02% |
| 2000 Q1 | 205.23 Thousand CAD | 0.0% |
| 1999 Q1 | 315.9 Thousand CAD | -14.59% |
| 1999 FY | 205.23 Thousand CAD | -35.03% |
| 1998 FY | 315.9 Thousand CAD | -16.91% |
| 1998 Q4 | 369.85 Thousand CAD | 8.63% |
| 1998 Q2 | 363.85 Thousand CAD | 0.0% |
| 1998 Q3 | 340.46 Thousand CAD | -6.43% |
| 1997 FY | 380.17 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Covalon Technologies Ltd. | 6.1 Million CAD | -9.385% |
| Hemostemix Inc. | 7.68 Million CAD | 13.064% |
| Universal Ibogaine Inc. | 2.37 Million CAD | -181.344% |
| Kane Biotech Inc. | 14.09 Million CAD | 52.585% |
| MedMira Inc. | 18.68 Million CAD | 64.241% |
| Marvel Biosciences Corp. | 2.39 Million CAD | -179.25% |
| NervGen Pharma Corp. | 15.24 Million CAD | 56.176% |
| XORTX Therapeutics Inc. | 1.08 Million CAD | -513.452% |